Mirum Pharmaceuticals
Stock Forecast, Prediction & Price Target
Mirum Pharmaceuticals (MIRM) stock Price Target by analysts
$70
Potential upside: 7.42%
Mirum Pharmaceuticals price prediction
What is Mirum Pharmaceuticals stock analysts` prediction?
Mirum Pharmaceuticals stock forecast: Based on 1 Wall Street analysts` predicted price targets for Mirum Pharmaceuticals in the last 3 months, the avarage price target is $70, with a high forecast of $NaN. The average price target represents a 7.42% change from the last price of $65.16.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Mirum Pharmaceuticals stock Price Target by analysts
Full breakdown of analysts given Mirum Pharmaceuticals price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Dae Gon Ha Stifel Nicolaus | 0% 0/2 | 11 months ago | $70 7.42% upside | $40.55 | StreetInsider | Previous targets (1) |
Brian Skorney Robert W. Baird | 0% 0/2 | about 1 year ago | $44 -32.47% downside | $38.96 | TheFly | Previous targets (1) |
Brian Skorney Robert W. Baird | 0% 0/2 | over 1 year ago | $39 -40.14% downside | $29.71 | StreetInsider | Previous targets (1) |
Ed Arce H.C. Wainwright | 0% 0/2 | over 1 year ago | $66 1.28% upside | $30.99 | TheFly | Previous targets (1) |
Gavin Clark-Gartner Evercore ISI | 0% 0/1 | over 1 year ago | $62 -4.84% downside | $33 | StreetInsider | Previous targets (0) |
Michael E Ulz Morgan Stanley | 0% 0/1 | over 1 year ago | $57 -12.52% downside | $33 | StreetInsider | Previous targets (0) |
Joshua Schimmer Cantor Fitzgerald | 0% 0/1 | over 1 year ago | $45 -30.93% downside | $25.75 | TheFly | Previous targets (0) |
Dae Gon Ha Stifel Nicolaus | 0% 0/2 | over 1 year ago | $48 -26.33% downside | $24.01 | TheFly | Previous targets (1) |
Ed Arce H.C. Wainwright | 0% 0/2 | over 1 year ago | $58 -10.98% downside | $28.17 | StreetInsider | Previous targets (1) |
Unknown Leerink Partners | N/A | over 2 years ago | $39 -40.14% downside | $20.02 | Benzinga | N/A |
Unknown Leerink Partners | N/A | almost 3 years ago | $50 -23.26% downside | $18.01 | Benzinga | N/A |
Unknown H.C. Wainwright | N/A | over 3 years ago | $69 5.89% upside | $24.31 | Benzinga | N/A |
Unknown Raymond James | N/A | over 3 years ago | $75 15.10% upside | $25.03 | Benzinga | N/A |
Unknown Leerink Partners | N/A | over 3 years ago | $49 -24.80% downside | $26.21 | Benzinga | N/A |
Mirum Pharmaceuticals Financial Estimates
Mirum Pharmaceuticals Revenue Estimates
Mirum Pharmaceuticals EBITDA Estimates
Mirum Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $19.13M N/A | $77.06M 302.66% | $186.37M 141.84% | Avg: $404.68M Low: $376.34M High: $481.40M avg. 117.13% | Avg: $506.91M Low: $483.24M High: $564.60M avg. 25.26% | Avg: $694.68M Low: $662.24M High: $773.75M avg. 37.04% | Avg: $865.54M Low: $825.12M High: $964.05M avg. 24.59% |
Net Income
% change YoY
| $-83.98M N/A | $-135.66M -61.52% | $-163.41M -20.45% | Avg: $-24.61M Low: $-84.22M High: $73.18M avg. 84.93% | Avg: $42.99M Low: $-59.09M High: $238.76M avg. 274.65% | Avg: $124.69M Low: $117.13M High: $143.14M avg. 190.04% | Avg: $197.33M Low: $185.36M High: $226.53M avg. 58.25% |
EBITDA
% change YoY
| $-64.65M N/A | $-126.99M -96.42% | $-136.49M -7.47% | Avg: $-42.69M Low: $-50.79M High: $-39.70M avg. 68.71% | Avg: $-53.48M Low: $-59.57M High: $-50.98M avg. -25.26% | Avg: $-73.29M Low: $-81.64M High: $-69.87M avg. -37.04% | Avg: $-91.32M Low: $-101.72M High: $-87.06M avg. -24.59% |
EPS
% change YoY
| -$2.77 N/A | -$4.01 -44.76% | -$4 0.24% | Avg: -$0.34 Low: -$2.06 High: $1.79 avg. 91.4% | Avg: $1 Low: -$1.45 High: $5.84 avg. 389.79% | Avg: $3.05 Low: $2.86 High: $3.5 avg. 205.94% | Avg: $4.83 Low: $4.53 High: $5.54 avg. 58.25% |
Operating Expenses
% change YoY
| $190.64M N/A | $195.90M 2.75% | $248.48M 26.83% | Avg: $569.21M Low: $529.36M High: $677.13M avg. 129.07% | Avg: $713.00M Low: $679.71M High: $794.15M avg. 25.26% | Avg: $977.12M Low: $931.50M High: $1.08B avg. 37.04% | Avg: $1.21B Low: $1.16B High: $1.35B avg. 24.59% |
FAQ
What is Mirum Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 151.97% in 2025-2028.
We have gathered data from 9 analysts. Their low estimate is -84.22M, average is -24.61M and high is 73.18M.
What is Mirum Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 51.00% in 2025-2028.
We have gathered data from 8 analysts. Their low revenue estimate is $376.34M, average is $404.68M and high is $481.40M.
What is Mirum Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 186.34% in 2025-2028.
We have gathered data from 9 analysts. Their low earnings per share estimate is -$2.06, average is -$0.34 and high is $1.79.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Mirum Pharmaceuticals stock. The most successful analyst is Dae Gon Ha.